Bay City Capital
Bay City Capital LLC (Bay City Capital), established in 1997 , specializes in investments in the life sciences industry.
Business Model:
Revenue: $8.4M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Bay City Capital Information
Geographic Data
Address: 750 Battery St
City: San Francisco
State: CA
Zip: 94111
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2M
Social
Twitter
Linkedin
Crunchbase
Metrics
7,558,103Website Global Rank
502Website Monthly Traffic
Twitter Followers
Description
Bay City Capital LLC (Bay City Capital) was established in 1997 for the purpose of managing investment funds in the life sciences industry. Since that date, they have managed six venture funds representing $1.5 billion in capital invested in over 70 companies. Five of these funds are general life sciences funds, and one is a nutrition and agribusiness sector fund.
Contact Phone:
+14156763830
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2013 | PharmAkea | Series A | 10M |
| 6/2011 | Aviir | Venture Round | 3M |
| 12/2014 | Interleukin Genetics | Post-IPO Equity | 5M |
| 4/2005 | Phenomix | Series B | 20M |
| 3/2009 | VIA Pharmaceuticals | Debt Financing | 10M |
| 4/2012 | Thermogenesis | Post-IPO Equity | - |
| 7/2018 | Gossamer Bio | Series B | 0 |
| 10/2017 | Gritstone Bio | Venture Round | - |
| 10/2013 | Cydan | Venture Round | 10M |
| 12/1997 | Chemdex | Seed Round | - |
| 3/2000 | AquaBounty Technologies | Venture Round | - |
| 11/2002 | Pathway Diagnostics | Venture Round | - |
| 3/2009 | Accriva Diagnostics | Venture Round | - |
| 7/2005 | BrainCells | Series A | 0 |
| 4/2000 | Ingenuity Systems | Venture Round | - |
| 3/2008 | IDEV Technologies | Series C | 14.4M |
| 5/2013 | Interleukin Genetics | Post-IPO Equity | 12M |
| 12/2002 | Bioren | Seed Round | - |
| 12/2004 | CymaBay Therapeutics | Series B | 44M |
| 2/2006 | NeoRX Corporation (Poniard Pharmaceuticals) | Post-IPO Equity | 65M |
| 3/1999 | VNUS Medical Technologies | Venture Round | - |
| 8/2004 | Avera Pharmaceutical | Series C | 0 |
| 8/2000 | Epocrates | Series B | 35M |
| 8/2007 | Presidio Pharmaceuticals | Series B | 26M |
| 8/2002 | Epocrates | Series C | - |
| 1/2005 | Calypso Medical | Series C | 6.8M |
| 5/2007 | Vivaldi Biosciences | Series A | 2M |
| 1/2018 | Oculis | Series B | 20.5M |
| 10/2014 | SynGen | Venture Round | - |
| 4/2012 | SynGen | Series A | 5M |
| 1/2002 | BioSeek | Venture Round | - |
| 5/2021 | Oculis | Series C | 0 |
| 11/2000 | Panomics | Seed Round | - |
| 2/2002 | Syntonix Pharmaceuticals | Series B | 35.8M |
| 10/2013 | Galecto | Series B | 6.3M |
| 1/2008 | Aragon Surgical | Series B | 25M |
| 3/2002 | Reliant Pharmaceuticals | Series C | 160M |
| 11/2009 | CymaBay Therapeutics | Series E | 0 |
| 1/1999 | Lexicon Pharmaceuticals | Post-IPO Equity | 0 |
| 2/2011 | Conatus Pharmaceuticals | Series B | 0 |
| 1/2010 | Merus | Series B | 0 |
| 9/2007 | Aciex Therapeutics | Series A | - |
| 1/2004 | PTC Therapeutics | Series E | 35M |
| 8/2000 | Intarcia Therapeutics | Venture Round | - |
| 8/2003 | CymaBay Therapeutics | Series A | 27M |
| 10/2016 | Bridge Medicines | Venture Round | - |
| 5/2017 | Xeris Pharmaceuticals | Series C | 0 |
| 4/2009 | Sunesis Pharmaceuticals | Post-IPO Equity | 0 |
| 9/2000 | Senomyx | Series B | 10M |
| 6/2017 | Twist Bioscience | Venture Round | 27M |
| 7/2016 | Vtesse | Series A | 17M |
| 10/2010 | IDEV Technologies | Series D | 46M |
| 9/2010 | EnteroMedics | Post-IPO Equity | 6.3M |
| 7/2004 | EnteroMedics | Series A | - |
| 3/2007 | Phenomix | Series C | 55M |
| 3/2010 | Ion Torrent | Series C | 37.1M |
| 11/1997 | Maxia Pharmaceuticals | Venture Round | - |
| 11/2000 | Helios Health | Venture Round | 0 |
| 6/2013 | Aviir | Series B | 10M |
| 6/2013 | Dermira | Series B | 35M |
| 11/2005 | PTC Therapeutics | Private Equity Round | 26.6M |
| 1/1999 | LJL Biosystems | Post-IPO Equity | - |
| 8/2005 | Protez Pharmaceuticals | Series B | 15M |
| 12/2008 | Aviir | Venture Round | 7.8M |
| 6/2009 | Hyperion Therapeutics | Series C | 60M |
| 4/2014 | Madrigal Pharmaceuticals | Post-IPO Equity | - |
| 9/2001 | PTC Therapeutics | Series D | 0 |
| 1/2014 | Fabric Genomics (formerly Omicia) | Series A | 6.8M |
| 1/2006 | MAP Pharmaceuticals | Series C | 25.2M |
| 9/2004 | MAP Pharmaceuticals | Series B | 30M |
| 10/2009 | Aviir | Venture Round | 1M |
| 6/2003 | Phenomix | Series A | 11.6M |
| 9/2006 | NuPathe | Series A | 15M |
| 10/2003 | Reliant Pharmaceuticals | Series D | 115M |
| 1/2016 | Imara | Seed Round | 800k |
| 11/2012 | Ascendancy | Venture Round | - |
| 5/2017 | Iterum Therapeutics | Series B | 65M |
| 11/2009 | Calypso Medical | Series E | 50M |
| 12/2003 | Avera Pharmaceutical | Series B | 8M |
| 7/2012 | GenturaDx | Series C | 21M |
| 10/2005 | Radiant Medical | Venture Round | 36M |
| 1/2010 | Aviir | Venture Round | 4.2M |
| 12/2011 | Aviir | Venture Round | 10M |
| 3/2008 | Aviir | Venture Round | 1.5M |
| 3/2007 | MAP Pharmaceuticals | Series D | 50M |
| 10/2020 | Sembiosys Genetics | Venture Round | - |
| 12/2006 | NBI Development | Seed Round | 5.5M |
| 1/1998 | Pharminex | Venture Round | - |
| 9/2007 | Aviir | Series B | 11.3M |
| 6/2004 | PTC Therapeutics | Series E | 0 |
| 9/2013 | Civitas Therapeutics | Series B | 0 |
| 4/2010 | Altheos | Series A | 20M |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 2/2012 | Altheos | Series A | 12.5M |
| 1/2018 | KBP Biosciences | Series A | 0 |
| 7/2004 | Phenomix | Series A | 2M |
| 3/2013 | Nabsys | Series D | 35M |
| 3/2019 | Imara | Series B | 0 |
| 10/2011 | Dermira | Series A | 42M |
| 2/2007 | PTC Therapeutics | Series F | 10M |
| 12/2006 | Nevro | Seed Round | 5.5M |
| 4/2016 | Imara | Series A | 31M |
| 1/2011 | NextWave Pharmaceuticals | Series C | 45M |
| 10/2002 | Oculex Pharmaceuticals | Series B | 50M |
| 4/2015 | Merus | Series C | 79.1M |
| 7/2011 | Nevro | Series B | 58M |
| 7/2013 | TRIA Beauty | Private Equity Round | 0 |
| 10/2013 | Merus | Series B | 42.2M |
| 9/2008 | Nevro | Series A | 21.8M |
| 10/2009 | Epizyme | Series B | 32M |
| 5/2007 | Conatus Pharmaceuticals | Series A | 22M |
| 8/2014 | Civitas Therapeutics | Series C | 0 |
| 10/2002 | Pharmion | Venture Round | 40M |
| 8/2014 | Dermira | Series C | 51M |
| 3/2002 | Phenomix | Series A | 12M |
| 1/2015 | Vtesse | Series A | 25M |
| 3/2013 | Nevro | Series C | 0 |
| 2/2009 | Cadence Pharmaceuticals | Post-IPO Equity | 86.6M |
| 3/2020 | Xilio Therapeutics | Series B | 100.5M |
| 2/2008 | Cadence Pharmaceuticals | Post-IPO Equity | - |
| 8/2000 | Syrrx | Series A | 5.1M |
| 6/2002 | Itamar Medical | Venture Round | - |
| 7/2008 | NuPathe | Series B | 30M |
| 1/2009 | Vivaldi Biosciences | Series A | 23M |
| 7/2017 | Kezar Life Sciences | Series B | 0 |
| 11/2020 | Bridge Medicines | Equity | 10M |
| 11/2018 | NextCure | Series B | 93M |
| 2/2013 | Aviir | Series B | 10M |
| 4/2002 | Avera Pharmaceutical | Series A | 20M |
| 3/2008 | BrainCells | Series B | 30M |
| 5/2021 | Oculis | Series C | 0 |
| 11/2020 | Bridge Medicines | Venture Round | 0 |
| 10/2020 | Sembiosys Genetics | Venture Round | - |
| 3/2020 | Xilio Therapeutics | Series B | 0 |
| 3/2019 | Imara | Series B | 0 |
| 11/2018 | NextCure | Series B | 0 |
| 7/2018 | Gossamer Bio | Series B | 0 |
| 1/2018 | KBP Biosciences | Series A | 0 |
| 1/2018 | Oculis | Series B | 0 |
| 10/2017 | Gritstone Bio | Venture Round | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
